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Background: Hepatitis B is the major cause of chronic hepatitis and cirrhosis in Iran. Sanitation and 
immunization is one of the most effective measures for prevention of the disease which is now wide-
ly used in developing countries. However, the immune response to the vaccine varies by age.
Objectives: To determine the effect of zinc sulfate on immune response to hepatitis-B vaccine in eld-
erly.
Patients and Methods: In a clinical trial on 140 subjects aged ≥40 years with a body mass index (BMI) 
<30 kg/m2, and without any co-morbid disease were recruited. Those who had negative hepatitis B 
core antibody (102 persons) were randomly allocated to two groups. The trial group received hepa-
titis B vaccine plus 200 mg zinc sulfate daily for 30 days and the control group received vaccine plus 
placebo.
Results: 52 of 102 people were female (51%). The two studied groups were comparable in terms of age, 
gender, and smoking habits. The mean antibody production in the intervention and control groups 
was 116.93 and 157.37 mIU/mL, respectively (p=0.22). No statistical differences were observed between 
the two groups in terms of proportion of people who were protected after vaccination (26.0% and 
36.5% in people with and without zinc, respectively).
Conclusions: This study revealed that zinc sulfate has no effect in level of immunity among elderly.
  Implication for Health policy/practice/research/medical education:
This article shows the effect of adding trace elements in response to routine vaccination program against hepatitis B virus. Reading this article is 
recommended especially for the personnel involved as primary health car workers.
  Please cite this paper as:
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Background
Hepatitis B is a major public health problem with two billion 
people infected worldwide (1). HBV is the most important cause 
of viral hepatitis in the world that can cause cirrhosis and liver 
cancer. More than 350 million people are chronic carriers of 
HBV and approximately 75% of them live in Asia and Africa (2). 
Two million people die of the disease annually in the world (3). 
The major routes of HBV transmission are via blood transfusion 
and  hemodialysis,  dental  surgery,  tattooing  and  drug  abuse 
(IDU). About 1.5 million people in Iran are living with HBV infec-
tion (2). The prevalence of infection in Iran is estimated to be 
2.14% in men and 2.55% in women. However, the prevalence of 
people with positive HBsAg varies between different provinces: 
Golestan (6.3%), Tehran (2.2%), East Azerbaijan (1.3%), Hamadan 
(2.3%), Isfahan (1.3%), Kermanshah province (1.3%) and Hormoz-
gan (2.4%) (4). It has been reported that the prevalence of people 
with positive HbsAg in Iran decreased from 2003 to 2005 (5). Vac-
cination is one of the most effective way of preventing disease, 
decreasing disability, and death from all infectious diseases (6). 
It seems that in endemic regions hepatitis B vaccination have a 
significant effect on reducing the chronic infection and carrier 
state, but may not reduce the infection rate (7). However, the im-
mune response to the vaccine is age dependent. Different stud-
ies as well as meta-analyses have shown that immune response 
to vaccines decreases by increasing age. This is why hospital ad-
mission rate has been increasing in elderly people. According 
to such studies between10% and 50% of the old age people can-
not be protected even after vaccination (6). In order to improve 
the immunogenicity of vaccination, different methods such as 
changes in vaccination method and adding supplements such 
as, levamisole, cimetidine, zinc sulfate and some other drugs 
have been investigated (8).
Objectives
This study was conducted to evaluate the effect of zinc sulfate 
as an adjuvant to increase the level of antibody production after 
hepatitis B vaccination in elderly.
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Patients and Methods
In a clinical trial conducted at Imam Reza Hospital, the main 
referral center in western Iran in Kermanshah province, from 
140 subjects over 40 years old, 102 that were negative for HBcAb 
(measured  by  competitive  ELISA,  Biomerieux,  USA),  enrolled 
into this study and randomly allocated into two intervention 
and control groups. Subjects were given detailed information 
about the study and written informed consent was obtained. A 
questionnaire including information regarding demographic 
factors, history of exposure to hepatitis B, any previous allergy, 
history of pervious hepatitis B vaccination was completed by 
trained interviewers. The intervention group was given hepati-
tis B vaccine (Hepavax, Korea) plus 200 mg zinc sulfate capsule 
(Alhavi, Iran); the control group was given hepatitis B vaccine 
(Hepavax, Korea) plus placebo (capsule filled by sugar). Three 
vaccination injections were given intra-muscularly using rapid 
method on the first day, and the next 10 days following, and fi-
nally in 22 days after the first injection (9) Anti-HBs antibody was 
measured by competitive ELISA (Biomerieux, USA) at the same 
hospital lab one month after the last vaccine injection in both 
groups. For the purpose of this study with assumption of 60% 
and 90% of people who reached to the protective level in control 
and trial group, we calculated a sample size of 102 people for the 
study to be able to reject the null hypothesis that the propor-
tion for trial and control groups are equal with a study power of 
0.95. Type I error probability was set to 0.05. Uncorrected x2 test 
was used to test the null hypothesis. Statistical analyses were 
performed using Stata ver 8. A p<0.05 was considered statisti-
cally significant. Mean serum antibody between two groups was 
compared by Student’s t test. To compare the number of people 
who were immune after vaccination in two groups we used x2 
test. Using univariate and multivariate logistic regression, we 
investigated the effect of different factors on seroconversion.
  
Variable       Univariate analysis (95% CI)        Multivariate analysis (95% CI)
Gender         1.9 (0.84–4.7)        1.68 (0.66–4.26)
(Female) 
Age       0.95 (0.89–1.0)        0.96 (0.91–1.0)
Smoking     0.87 (0.16–4.7)                            0.95 (0.19–5.9)
BMI      0.92 (0.76–1.11)        0.91 (0.74–1.12)
Group           0.61 (0.26–1.42)        0.64 (0.26–1.56)
(trial)  
  
Variable                             With Zinc (n=50)           Without Zinc (n=52)           p - value
Gender                        50                  51.9                       0.85
(Female %)
Age (Mean±SD, year)  49.1±8.0                  48.4±8.3                       0.67
Smoking (%)               4.0                  9.6                       0.26
BMI                       25.8±2.0                  25.2±2.3                       0.14
Ab level                       116.93                  157.37                       0.22
(mIU/mL)
Immunity (%)            26.0                  36.5                       0.25
Figure 1. Percentage of immunized people among two sexes
Figure 2. Percentage of immunized people among two sexes
Results
The subject of this study included 52 women (51.0%) and 50 
men (49.0%). Out of the 102 participants, seven (6.9%) were ciga-
rette smokers (4% in the intervention and 9.6% in the control 
group). From 102 participants, 50 in the trial group received 
zinc sulfate with three injections of the vaccine. The median 
age of participants was 47 (range: 40–73) years. There were no 
statistical significant differences between the intervention and 
control groups in terms of main confounding and background 
variables  such  as  gender,  age  and  smoking  habits  and  body 
mass index (BMI) (all p>0.1) (Table 1). Comparing mean antibody 
level and the proportion of people who reached the protective 
level, both groups were similar (Table 1). While the distribution 
of male and female participants among trial and control groups 
was similar (Table 1), in both groups slightly greater proportion 
of females reached the protective level (Figure 1). Similar find-
ings were observed when we compared the mean of natural log-
arithm of antibody level in two sexes in both groups (3.2±2.3 and 
3.3±2.0 among males in the control and intervention groups, re-
spectively, and 3.8±2.4 and 3.1±2.3 among females in the control 
and trial groups, respectively). While the proportion of smokers 
among two groups was similar (Table 1), smoking has no signifi-
cant effects on the proportion of immunized people after three 
vaccine injections (Table 2). None of smokers in the trial group 
developed the protective antibody level (Figure 2). The mean age 
among the studied groups was also  similar (Table 1). Although 
non-statistically significantly, the proportion of protected peo-
ple decreased by growing age in both univariate and multivari-
able analyses (Table 2). Figure 3 shows the mean of log Ab level in 
both groups by age. Table 2 shows the result of univaritate and 
multivariate analyses of all variables including “group” on final 
immunity after three vaccine injections. After adjustment, none 
of the studied variables had effect on immunity.
 
Table 1. Comparison of characteristics and Ab level among the two groups
Table 2. Effect of different factors on immunity after hepatitis B vaccination us-
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Figure 3. Percentage of immunized people by smoking status
Discussion
Zinc is an essential micronutrient for human metabolism that 
catalyzes more than 100 enzymes, facilitates protein folding, and 
helps to regulate gene expression. Patients with malnutrition, 
alcoholism,  inflammatory  bowel  disease,  and  malabsorption 
syndromes are at increased risk of zinc deficiency. Symptoms of 
zinc deficiency are nonspecific, including growth retardation, 
diarrhea, alopecia, glossitis, nail dystrophy, decreased immu-
nity, and hypogonadism in males. In developing countries, zinc 
supplementation may be effective for the prevention of upper 
respiratory infection and diarrhea, and as an adjunct treatment 
for diarrhea in malnourished children. However, current data 
do not support the positive effect of zinc supplementation on, 
wound healing, or human immunodeficiency virus. Zinc is well-
tolerated  at  recommended  dosages.  However,  adverse  effects 
of  long-term  and  high-dose  zinc  consumption  are:  effect  on 
decrease in immunity and high-density lipoprotein cholesterol 
levels, anemia, copper deficiency, and possible genitourinary 
complications (10). All kinds of immune cells show decreased 
function after zinc depletion. In such situation, all functions 
related to monocytes and T cells are impaired, in natural killer 
cells and neutrophils cytotoxicity activity and phagocytosis is 
reduced, respectively. However, auto-reactivity and all reactivity 
will increase (11). In fact, enhancing the immune response to the 
vaccination after hepatitis B among older peoples is one of the 
most important issues. There are large number of studies inves-
tigating the different methods for increasing the immune re-
sponse after vaccination such as use of different adjuvants (such 
as levamisole, cimetedine and zinc sulfate), different methods 
of vaccination (whether intradermal or intramuscular as well 
as rapid or conventional methods). For example, vaccination via 
the intradermal route (ID) is considered as a method that may be 
more effective than the conventional intramuscular (IM) route 
(12). However, such general belief is not supported by findings 
from all studies (13). While other factors such as smoking status, 
BMI, and age may have effect on Ab production after vaccination, 
effect of different adjuvants have been investigated in different 
studies. It is generally believed that addition of levamisole to 
hepatitis B vaccine can enhance the immunological response 
(12). Regarding the use of zinc, while there are some controver-
sies on the effect of zinc supplementation on immune status, it 
has been suggested that daily use of up to 40 mg zinc has no ad-
verse effects on immune status of healthy people (14). However, 
different studies investigating the effect of zinc on proportion 
of seroconversion showed no effect (15, 16). One study about the 
effect of zinc sulfate on increasing antibody response in hemo-
dialysis patients was done in Italy in 1990. This study showed 
50% increase in antibody production in non-responders (mean 
antibody production was 124.6 mIU/mL) (15). Another study on 
the effect of zinc sulfate on increasing antibody response in he-
modialysis patients was done in Holland in 1991. In that study 
the patients was categorized into two groups (n=7, each group). 
In one group, hepatitis B vaccine with zinc sulfate was given and 
in another group hepatitis B vaccine without zinc sulfate was 
administered. Results showed no difference in antibody produc-
tion between the two studied groups (16). Another study on the 
effect of zinc sulfate on increasing antibody response in elderly 
people was done in Ireland in 2007. In this study, one group re-
ceived zinc sulfate capsules, 15 mg daily for six months; the other 
group was given 40 mg zinc sulfate daily for six months. Result 
showed no difference in the antibody production between the 
two study groups (14). According to the results of some studies 
that discussed previously we thought that zinc might stimulate 
antibody  response  in  the  non-responders  to  hepatitis  B  vac-
cine. One of the most important of non-responder groups are 
old people. This study showed no statistical difference between 
the two study groups in terms of gender and weight in antibody 
production. Random allocation of people into two groups cre-
ated a similar distribution of all background and confounding 
variables between two studied groups. After adjustment for all 
other variables, there was no effect for smoking, group and sex 
on seroconversion. It is worth mentioning that for the purpose 
of this study we used accelerated method for vaccination and 
that may contribute to our final results regarding no effect in 
the seroconversion of people allocated to two groups. Acceler-
ated HB vaccination can shorten duration of immunization we 
performed this clinical trial for showing its effectiveness (9). 
Future studies should aim at investigating the effect of zinc sul-
fate on seroconversion after a simple method vaccination (0, 1 
m, 6 m). On the other hand, future studies need to have a larger 
sample size to find out possible effects of zinc as well as other 
variables such as age, gender, smoking and BMI, since in the 
current study, it is difficult to explain the independent effects 
of such variables.
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